Navigation Links
SciClone Pharmaceuticals To Report Financial Results For The Third Quarter 2015 On November 9th
Date:10/26/2015

FOSTER CITY, Calif., Oct. 26, 2015 /PRNewswire/ -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the third quarter 2015 on Monday, November 9, 2015. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET (1:30 pm PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.

 

LIVE CALL:

877.674.6420 (US/Canada)920.663.6281 (International)Passcode: 57951261


The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com.  The information provided on the teleconference is accurate only at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.

About SciClone

SciClone Pharmaceuticals is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone's proprietary lead product, ZADAXIN® (thymalfasin), is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Through its promotion business with pharmaceutical partners, SciClone also markets multiple branded products in China which are therapeutically differentiated. SciClone is a publicly-held corporation based in Foster City, California, and trades on the NASDAQ Global Select Market under the symbol SCLN. For additional information, please visit www.sciclone.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding expected financial results and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially.  Please also refer to other risks and uncertainties described in SciClone's filings with the SEC. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements.

SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals design, the SciClone logo and ZADAXIN are registered trademarks of SciClone Pharmaceuticals, Inc. in the United States and numerous other countries.Corporate Contacts Wilson W. Cheung 

Jane GreenChief Financial Officer

Investors/Media 650.358.3434 

650.358.1447wcheung@sciclone.com 

jgreen@sciclone.com

Logo - http://photos.prnewswire.com/prnh/20150722/240358LOGO

 


'/>"/>
SOURCE SciClone Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. SciClone To Present At Two Investor Conferences On September 10, 2015
2. SciClone To Present At 2015 Aegis Capital Growth Conference On October 9th
3. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
4. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
5. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
6. Access Pharmaceuticals Reports First Quarter Results
7. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
8. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
9. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
10. Aveo Pharmaceuticals, Inc. Sued by Investor
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/7/2020)... ... April 07, 2020 , ... ... medical clinics close or have limited availability, patients suffering from many different medical ... centers, emergency rooms, and even hospitals. That is why it is so essential ...
(Date:4/5/2020)... ... April 04, 2020 , ... In a time ... a factory producing non-medical cloth facemasks. , On March 18th when SwaddleDesigns (located ... non-medical cloth face masks if no medical-grade facemasks were available, SwaddleDesigns founder& CEO, ...
(Date:4/5/2020)... ... April 05, 2020 , ... INTRODUCTION , As ... and pathology of COVID-19[1], we are committed to the non-profit dissemination of our ... The SARS-CoV-2-mediated post-entry suppression of ACE2 mRNA expression in host cells is one ...
Breaking Medicine Technology:
(Date:4/5/2020)... ... 2020 , ... In the midst of crisis, the entire ... proprietary biomaterial company that seamlessly embeds active ingredients including vitamins, supplements and medications ... production for a new line of reusable copper medical masks called TheraMasks. These ...
(Date:4/2/2020)... ... April 02, 2020 , ... ... An FDAnews Webinar, Tuesday April 7, 2020, 1:30-3:00 p.m. EDT, https://www.fdanews.com/cdssoftwareregulation ... regulation of AI used to guide clinical management of the Coronavirus.* , Is ...
(Date:4/2/2020)... ... 02, 2020 , ... The Northern Virginia Community College Educational Foundation (NOVA Foundation) ... Howe of Palm Beach, Florida. Ms. Howe is adding to her existing endowed ... is more important than ever given the current pandemic. Ms. Howe has also generously ...
(Date:4/2/2020)... ... 2020 , ... Representatives fighting for children born exposed ... and guardians, to file a proof of claim in order to qualify to ... available by Purdue as part of its bankruptcy settlement. , “The COVID-19 national ...
(Date:4/1/2020)... ... April 02, 2020 , ... Medical Device Change Management, An ... https://www.fdanews.com/mdchangemanagement , What change management method should one be using for a ... dependent on the type of change. Is it due to post-market design change, production ...
Breaking Medicine News(10 mins):